Malvern

Researchers are conducting a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the safety and effectiveness of KarXT in men and women aged 55 to 90 years who have mild to severe Alzheimer's Disease with moderate to severe psychosis related to the condition. The main goal is to compare KarXT against a placebo by measuring changes in hallucinations and delusions using the Neuropsychiatric Inventory-Clinician (NPI-C) score. Participants will receive different doses of KarXT ranging from 20/2 mg to 66.7/6.67 mg daily or placebo capsules. The study is designed to compare the effects of KarXT with placebo in a parallel group format, maintaining the double-blind setup to ensure unbiased results. During the study, participants will be assessed at the start and end of treatment (up to 14 weeks) to evaluate changes in psychotic symptoms. They will undergo clinical scales such as the NPI-C and the Clinical Global Impression-Severity (CGI-S) scale. The study also requires imaging scans like MRI or CT to rule out other brain diseases. A study partner who has regular contact with the participant will be involved to support adherence and observation. Safety and efficacy will be monitored throughout the treatment period.

This research analyzes previously collected data from patients treated for mental health conditions such as depression, OCD, and anxiety depression at Greenbrook. The goal is to better understand how various treatments were used and how effective they were. This retrospective study reviews clinical care data starting from 2011 onward to assess treatment outcomes. The analysis focuses on patients who received treatments like NeuroStar TMS, a non-invasive brain stimulation device, and Esketamine, a nasal spray for depression. These treatments and their application details are examined through the available data without any new interventions. The study uses existing records to compare treatment utilization and results. Participants' data include clinical outcome scores measured before and after treatment, specifically changes over an 8-week period. Researchers review treatment parameters and patient information recorded in the database to evaluate mental health improvements. Since this is a retrospective study, no new visits or procedures are required from participants, and the focus is on analyzing existing treatment data for effectiveness and usage patterns.

Researchers are using real-world data to better understand how patient characteristics, symptoms, and treatment settings affect clinical outcomes with the NeuroStar Transcranial Magnetic Stimulation (TMS) device. The study focuses on patients treated for depression, obsessive-compulsive disorder, and anxiety depression. By analyzing this data, the study aims to evaluate the effectiveness of the NeuroStar TMS therapy in real clinical settings. The intervention being studied is the NeuroStar Advanced TMS Therapy System, a non-invasive brain stimulation device. The study looks at treatments recorded from November 1, 2008, onward, using information collected during routine care. No additional treatments or procedures are administered as part of this retrospective analysis. Participants' data are reviewed to assess changes in clinical assessment scores from the start of treatment to eight weeks after. Researchers examine how different factors, including patient symptoms and TMS protocol parameters, relate to treatment outcomes. The study relies on existing medical records and treatment information, with no direct participant involvement or new assessments conducted.